To evaluate the effect of niacinamide, on selected parameters of osteoarthritis using a doubleblind, placebo controlled study design.
Seventy two patients with osteoarthritis were randomized for treatment with niacinamide or an identical placebo for 12 weeks. Outcome measures included global arthritis impact and pain, joint range of motion and flexibility, erythrocyte sedimentation rate, complete blood count, liver function tests, cholesterol, uric acid, and fasting blood sugar. Compliance was monitored with a pill record sheet and interview.
Global arthritis impact improved by 29% (95% confidence interval [CI] 6, 46) in subjects on niacinamide and worsened by 10% in placebo subjects (p=0.04). Pain levels did not change but those on niacinamide reduced their anti-inflammatory medications by 13% (95% CI 9, 94; p=0.01). Niacinamide reduced erythrocyte sedimentation rate by 22% (95% CI 6, 51; p<0.005) and increased joint mobility by 4.5 degrees over controls (8 degrees vs. 3.5 degrees; p=0.04). Side effects were mild but higher in the niacinamide group (40% vs 27%, p=0.003).
This study indicates that niacinamide may have a role in the treatment of osteoarthritis. Niacinamide improved the global impact of osteoarthritis, improved joint flexibility, reduced inflammation, and allowed for reduction in standard anti-inflammatory medications when compared to placebo. More extensive evaluation of niacinamide in arthritis is warranted.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Altman RD. Overview of osteoarthritis. Am J Med 1987;83:65–9.
Dieppe PA, Frankel SJ, Toth B. Is research into the treatment of osteoarthritis with non-steroidal anti-inflammatory drugs misdirected? Lancet 1993;341:353–4.
Kaufman W. Niacinamide therapy for joint mobility: Therapeutic reversal of a common clinical manifestation of the normal aging process. Conn State Med J 1953;17:584–9.
Kaufman W. The use of vitamin therapy to reverse certain concomitants of aging. J Am Geriatr Soc 1955;3:927–36.
Hoffer A. Treatment of arthritis by nicotinic acid and nicotinamide. Can Med Assoc J 1959;8:235–8.
Kaufman W. The common form of joint dysfunction: Its incidence and treatment. Brattleboro, E.L. Hildreth & Company, 1949.
DiPalma JR, Thayer WS. Use of niacin as a drug. Ann Rev Nutr 1991;11:169–87.
Mosher LR. Nicotinic acid side effects and toxicity: A review. Amer J Psychiat 1970;126:124–9.
Altman R, Asch E, Boch D, et al. Development of criteria for classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthr Rheum 1986;29:1039–49.
Joint motion measurement. U.S. Army Training Circular TC 8-640 (No. 8-640), 1987:1–3.
Meenan RF, Gertman PM, Mason JH. Measuring health status in arthritis: The arthritis impact measurement scales. Arthr Rheum 1980;23:146–52.
Drugs for pain. Med Lett 1993;35:1–6.
Sackett DL, Haynes RB, Guyatt GH, Tugwell P, editors. Clinical Epidemiology. Boston: Little, Brown & Company, 1991:214–5.
Bernstein DS. Studies on glucose metabolism in cartilage in vitro. Proc Soc Exp Biol Med 1961;107:456–9.
Hamerman D. The biology of osteoarthritis. NEJM 1989;320:1322–30.
Hess EV, Herman JH. Cartilage metabolism and anti-inflammatory drugs in osteoarthritis. Am J Med 1986;81 Suppl 5B:36–43.
accepted by R. O. Day
About this article
Cite this article
Jonas, W.B., Rapoza, C.P. & Blair, W.F. The effect of niacinamide on osteoarthritis: A pilot study. Inflamm Res 45, 330–334 (1996). https://doi.org/10.1007/BF02252945
- Randomized controlled trial